No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
XERS240517P1500
- 0.05
- 0.000.00%
15min DelayClose May 7 13:25 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume21 Open Interest1.50Strike Price0.00Turnover163.39%IV-22.87%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type-0.1640Delta0.4884Gamma37.60Leverage Ratio-0.0063Theta-0.0001Rho-6.17Eff Leverage0.0008Vega
Intraday
- 5D
- 1D
News
Why Are Xeris Biopharma Shares Moving Monday?
Xeris Biopharma Holdings, Inc (NASDAQ:XERS) shares are up Monday after the company announced an exclusive worldwide collaboration and license agreement with Beta Bionics.What Happened: In a new press
Craig-Hallum Sticks to Their Buy Rating for Xeris Pharmaceuticals (XERS)
Xeris Biopharma Collaborating With Beta Bionics for Development, Commercialization of Glucagon Product
Xeris Biopharma Holdings (XERS) said Monday it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics for the development and commercialization of a glucagon pro
Express News | Xeris Shares Are Trading Higher After the Company Announced an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics
Express News | Xeris Biopharma: Potential to Get Development Payments, Plus Low Double-Digit Royalties Based on Future Sales of Xeris Glucagon for Pumps, Pump Systems
Express News | Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics
Comments
$Xeris Pharmaceuticals(XERS.US$ Reuters· 1 min ago
Xeris Biopharma: Potential to Get Development Payments, Plus Low Double-Digit Royalties Based on Future Sales of Xeris Glucagon for Pumps, Pump Systems
Xeris Biopharma: Potential to Get Development Payments, Plus Low Double-Digit Royalties Based on Future Sales of Xeris Glucagon for Pumps, Pump Systems
Despite Xeris Biopharma Holdings' strong performance, its growth projections are subdued compared to the industry. This could lead to a share price decline if the P/S ratio falls to align with the growth outlook.
$Xeris Pharmaceuticals(XERS.US$Moomoo 24/7· 1 min ago1min
Xeris Biopharma Enters Into An Exclusive Worldwide License Agreement With Amgen For Xeriject Formulation Of Teprotumumab For Thyroid Eye Disease; Xeris Has The Potential To Receive $75M In Development And Regulatory Milestones![]()
Xeris Biopharma Enters Into An Exclusive Worldwide License Agreement With Amgen For Xeriject Formulation Of Teprotumumab For Thyroid Eye Disease; Xeris Has The Potential To Receive $75M In Development And Regulatory Milestones
Read more